The Cicada COVID variant, an offshoot of the Omicron family, has raised concerns in India due to its significant mutations.
The Cicada COVID-19 variant, classified as BA.3.2 and part of the Omicron family, has recently emerged as a topic of concern in India. This variant was first identified in South Africa in November 2024 and has since spread to at least 22 countries, raising alarms among health officials worldwide.
As of now, the Cicada variant is noted for having over 75 mutations compared to the original Wuhan strain, with more than 50 of these mutations occurring in the spike protein. This extensive mutation profile has led to questions about its potential impact on transmissibility and vaccine effectiveness.
Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. However, it is important to note that the variant has not been confirmed to cause more severe illness than previous variants.
The first confirmed case of the Cicada variant in the United States was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered. This timeline indicates that while the variant is spreading, it may not necessarily lead to increased severity of illness.
Dr. Robert Hopkins Jr. has commented on the situation, stating, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the uncertainty surrounding the variant’s potential to outpace other strains.
The Centers for Disease Control and Prevention (CDC) has emphasized the importance of monitoring the spread of BA.3.2, as it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.
As the situation develops, health authorities in India and around the world are closely watching the Cicada variant. Details remain unconfirmed regarding its overall impact on public health and the effectiveness of current vaccines against it.
In summary, the emergence of the Cicada COVID variant underscores the ongoing challenges posed by the pandemic. Continued vigilance and research are essential to understanding and mitigating the effects of this new variant on global health.
